RSS   Newsletter   Contact   Advertise with us
Post Online Media

RXi Pharmaceuticals appoints Noah D. Beerman as president and CEO

Share on Twitter Share on LinkedIn
Staff writer | Worcester, Mass., USA | Friday November 6, 2009 8:24AM ET
RXi Pharmaceuticals November 6, 2009, Worcester, Mass., USA - RXi Pharmaceuticals Corporation announced that Noah D. Beerman has joined the company as its new president and chief executive officer.
Mr. Beerman joins RXi with over 25 years of experience in the biopharmaceutical industry and most recently served as Executive Vice President, Chief Business Officer for Indevus Pharmaceuticals, Inc., which was acquired by Endo Pharmaceuticals in March 2009.

Mr. Beerman was also responsible for overseeing Indevus' acquisition of Valera Pharmaceuticals in 2007 and for managing the integration activities with Endo as part of this transaction.

Prior to joining Indevus in 1997, Mr. Beerman was Vice President responsible for health care at Technology Management and Funding (TMF), a venture firm where he developed and executed business and commercialization strategies for TMF's biotechnology portfolio.

Earlier in his career, he served in a variety of business and scientific capacities at Creative BioMolecules, Sandoz AG, and Repligen.

Mr. Beerman holds an M.B.A. from Northeastern University's High Technology Program and a B.S. in molecular genetics from the University of Rochester.

 

 LATEST MOVES FROM Massachusetts 


POST Online Media Contact

 More inside POST